CUMYL-CB-MEGACLONE
Designer drug
Pharmaceutical compound
|  | |
| Legal status | |
|---|---|
| Legal status | 
 | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H26N2O | 
| Molar mass | 370.496 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
CUMYL-CB-MEGACLONE (CUMYL-CBMGACLONE, SGT-273) is a gamma-carboline based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Hungary in April 2020.[1]
See also
[edit]- 5F-CUMYL-PEGACLONE
- CUMYL-5F-P7AICA
- CUMYL-CH-MEGACLONE
- CUMYL-BC-HPMEGACLONE-221
- CUMYL-CBMINACA
- CUMYL-THPINACA
References
[edit]| Receptor (ligands) | 
 | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (modulators) | 
 | ||||||||||||||||||||||||||||||
| Enzyme (modulators) | 
 | ||||||||||||||||||||||||||||||
| Others | 
 | ||||||||||||||||||||||||||||||
| 
 | |||||||||||||||||||||||||||||||
|  | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |